Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Dec 20;54(4):265-274.
doi: 10.28920/dhm54.4.265-274.

Economic analysis of hyperbaric oxygen therapy for the treatment of ischaemic diabetic foot ulcers

Affiliations
Randomized Controlled Trial

Economic analysis of hyperbaric oxygen therapy for the treatment of ischaemic diabetic foot ulcers

Robin J Brouwer et al. Diving Hyperb Med. .

Abstract

Introduction: The aim was to determine the cost-effectiveness and cost-utility of additional hyperbaric oxygen therapy (HBOT) compared to standard care (SC) for ischaemic diabetic foot ulcers (DFUs) regarding limb salvage and health status.

Methods: An economic analysis was conducted, comprising cost-effectiveness and cost-utility analyses, with a 12-month time horizon, using data from the DAMO₂CLES multicentre randomised clinical trial. Cost-effectiveness was defined as cost per limb saved and cost-utility as cost per quality-adjusted life year (QALY). The difference in cost effectiveness between HBOT+SC and SC alone was determined via an incremental cost-effectiveness ratio (ICER).

Results: One-hundred and twenty patients were included, with 60 allocated to HBOT+SC and 60 to SC. No significant cost difference was found in the intention-to-treat analysis: €3,791 (bias corrected and accelerated [BCA] 95% CI, €3,556 - €-11,138). Cost per limb saved showed an ICER of €37,912 (BCA 95% CI €-112,188 - €1,063,561) for HBOT+SC vs. SC. There was no significant difference in mean QALYs: 0.54 for HBOT+SC vs. 0.56 for SC alone (-0.02; BCA 95% CI -0.11-0.08). This resulted in a cost-utility of minus €227,035 (BCA 95% CI €-361,569,550 - €-52,588) per QALY. Subgroup analysis for Wagner stages III/IV showed an ICER of €19,005 (BCA 95%CI, -€18,487 - €264,334) while HBOT did not show any benefit for Wagner stage II.

Conclusions: HBOT as an adjunct to SC showed no significant differences in costs and effectiveness for patients with DFUs regarding limb salvage and health status. However, for patients with Wagner stage III/IV ischaemic DFUs there was a trend towards better effectiveness and cost-effectiveness.

Keywords: Cost-effectiveness; Peripheral arterial occlusive disease; Wound healing.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest were declared.

References

    1. World Health Organisation . WHO Fact Sheet 312: diabetes. [Internet]. [cited 2019 August 1]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/diabetes.
    1. Boulton AJ. The pathway to foot ulceration in diabetes. Med Clin North Am. 2013;97 - PubMed
    1. Claessen H, Narres M, Haastert B, Arend W, Hoffmann F, Morbach S, et al. Lower-extremity amputations in people with and without diabetes in Germany, 2008–2012 – an analysis of more than 30 million inhabitants. Clin Epidemiol. 2018;10:475–88. doi: 10.2147/CLEP.S146484. - DOI - PMC - PubMed
    1. Lombardo FL, Maggini M, De Bellis A, Seghieri G, Anichini R. Lower extremity amputations in persons with and without diabetes in Italy: 2001–2010. PLoS One. 2014;9(1):e86405. doi: 10.1371/journal.pone.0086405. - DOI - PMC - PubMed
    1. Schaper NC, Van Netten JJ, Apelqvist J, Lipsky BA, Bakker K. Prevention and management of foot problems in diabetes: a summary guidance for daily practice 2015, based on the IWGDF guidance documents. Diabetes Metab Res Rev. 2016;32(Suppl 1):7–15. doi: 10.1002/dmrr.2695. - DOI - PubMed

Publication types

LinkOut - more resources